Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | BCL9 | O00512 | 17/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 17/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124512 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2BCL9 | |
| Fumaric Acid SCHEMBL4124161 | 0.91 | BCL9 (0.46) | KCNH2BCL9CTNNB1 | |
| Fumaric Acid SCHEMBL4124157 | 0.91 | BCL9 (0.46) | KCNH2BCL9CTNNB1 | |
| Fumaric Acid SCHEMBL4124148 | 0.91 | BCL9 (0.46) | KCNH2BCL9CTNNB1 | |
| SCHEMBL4124503 | 0.90 | CHRM1 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2BCL9 | |
| SCHEMBL4124153 | 0.90 | KCNH2 (0.44) | SLC6A2SLC6A4SLC6A3KCNH2BCL9 | |
| SCHEMBL4124510 | 0.90 | CHRM1 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2BCL9 | |
| SCHEMBL4124159 | 0.90 | KCNH2 (0.44) | SLC6A2SLC6A4SLC6A3KCNH2BCL9 | |
| SCHEMBL4132656 | 0.88 | NAAA (0.44) | SLC6A2SLC6A4SLC6A3KCNH2BCL9 | |
| SCHEMBL4132660 | 0.88 | NAAA (0.44) | SLC6A2SLC6A4SLC6A3KCNH2BCL9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215857-A1 | Therapeutic Pyrrolidines | PFIZER PRODUCTS INC. (US) | 2009-08-27 | — | — | US | claimed |
| EP-1931653-A2 | THERAPEUTIC PYRROLIDINES | Pfizer Products Inc. (US) | 2008-06-18 | — | — | EP | claimed |
| WO-2007031828-A2 | THERAPEUTIC PYRROLIDINES | PFIZER PRODUCTS INC. (US) | 2007-03-22 | — | — | WO | claimed |
| US-20090215857-A1 | Therapeutic Pyrrolidines | PFIZER PRODUCTS INC. (US) | 2009-08-27 | — | — | US | disclosed |
| EP-1931653-A2 | THERAPEUTIC PYRROLIDINES | Pfizer Products Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007031828-A2 | THERAPEUTIC PYRROLIDINES | PFIZER PRODUCTS INC. (US) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215857-A1 | Therapeutic Pyrrolidines | OPRL1, HTR5A, OPRD1 | SLC6A2 28/4885SLC6A4 18/4885SLC6A3 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.